FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588893060> ?p ?o ?g. }

• W2588893060 abstract "Abstract Abstract 172 Background. Dasatinib (Sprycel®) is a potent inhibitor of BCR-ABL and SRC family kinases. Based on the rapid and clinically meaningful activity observed when dasatinib was used as a single agent a consensus has been reached by the EWALL (European Working Group for Adult ALL) to conduct an international study evaluating the combination of dasatinib and low-intensity chemotherapy in patients with Ph+ ALL aged 55 years or more. Patients and Methods. After a prephase with dexamethasone 10 mg/m2 d-7 to d-3, dasatinib was administered at 140 mg QD (100 mg in patients over 70y) during the induction period in combination with IV injections of vincristine 1 mg and dexamethasone 40 mg 2 days (20 mg over 70y) repeated weekly for 4 weeks. Consolidation cycles consisted of dasatinib 100 mg/d administered sequentially with methotrexate 1000 mg/m2 IV d1 (500 mg/m2 over 70y) and L-asparaginase 10,000 UI/m2 IM d2 (5,000 UI/m2 over 70y) for cycles 1, 3 and 5 and cytarabine 1,000 mg/m2/12h IV d1, d3, d5 (500 mg/m2 over 70y) for cycles 2, 4 and 6. Maintenance phase consisted of dasatinib alternating with 6-MP and methotrexate orally every other month and dexamethasone/vincristine once every 2 months for up to 24 months. Patients were molecularly monitored by a central laboratory for BCR-ABL RTQ-PCR and T315I resistance mutation ASO RTQ-PCR. Results. Seventy one patients were included from August 2007 to study termination in May 2010. Median age was 69.1 years (range: 58–83). Median follow-up was 16.3 months. At diagnosis, the Ph chromosome was associated with other abnormalities (complex, -7, Ph duplication or others) in 64.5% of cases. The CR rate after induction was 90% and 55.7% of the patients achieved a BCR-ABL/ABL ratio ≤0.1% at the time of CR. Failure to achieve CR was mainly related to death (n=5.7%). Serious adverse events (SAEs) during induction were infections (11%), elevated transaminases (7%), hemorrhage (5.6%), renal failure due to tumor lysis syndrome (4.2%) and cardiovascular events (5.6%). Only 2 pleural effusions were observed. During consolidation and maintenance, most frequent SAEs were infections (33.3%). One pleural effusion was observed. Nineteen patients relapsed after a median response duration of 19.2 weeks and 12 of them died. Thirteen patients presented mutations in the BCR-ABL TK domain at relapse (12 T315I, 1 F317L), no mutation was detected in 3 patients and results are pending in 3 patients. T315I ASO RTQ-PCR analysis during follow-up was predictive for relapse. The rise of the T315I signal over 0.1% was always associated with relapse and occurred 1 to 3 months before relapse in 6 of the 12 T315I cases and concomitantly in the 6 remaining patients. Four patients received RIC allogenic stem cell transplantation and were censored at the time of SCT. Median RFS and OS were 22.1 and 27.1 months, respectively. Cytogenetics findings at diagnosis were good predictors for RFS: the median RFS for patients with isolated Ph was not reached while it was 19.2 months in patients with additional cytogenetic abnormalities (p=0.03)). Molecular BCR-ABL transcript level after induction had no effect on RFS. However, a BCR-ABL ratio ≤0.1% after induction and then confirmed during consolidation was significantly associated with a better RFS (5.1 months versus not reached, p=0.006). Conclusions. Dasatinib combined with low-intensity chemotherapy is highly effective in elderly patients with Ph-positive ALL with a 90% CR rate and a 22.1 months RFS. Cytogenetics at diagnosis is a strong predictive factor for RFS. Most relapses were associated with the T315I mutation. Serial monitoring for T315I allowed us to predict for hematological relapse and may offer an opportunity to adapt therapy before relapse. Disclosures: Rousselot: Bristol Myers Squibb: Research Funding. Off Label Use: Dasatinib as first line therapy in Ph ALL." @default.
• W2588893060 created "2017-02-24" @default.
• W2588893060 creator A5000000264 @default.
• W2588893060 creator A5000436961 @default.
• W2588893060 creator A5003760824 @default.
• W2588893060 creator A5004450449 @default.
• W2588893060 creator A5007895303 @default.
• W2588893060 creator A5010990164 @default.
• W2588893060 creator A5015832963 @default.
• W2588893060 creator A5025168447 @default.
• W2588893060 creator A5025907897 @default.
• W2588893060 creator A5027248801 @default.
• W2588893060 creator A5030574503 @default.
• W2588893060 creator A5035348501 @default.
• W2588893060 creator A5037324033 @default.
• W2588893060 creator A5037888163 @default.
• W2588893060 creator A5039996784 @default.
• W2588893060 creator A5042552205 @default.
• W2588893060 creator A5045283637 @default.
• W2588893060 creator A5052564121 @default.
• W2588893060 creator A5055343627 @default.
• W2588893060 creator A5064625563 @default.
• W2588893060 creator A5066213019 @default.
• W2588893060 creator A5067318724 @default.
• W2588893060 creator A5076521693 @default.
• W2588893060 creator A5076870917 @default.
• W2588893060 creator A5078817313 @default.
• W2588893060 creator A5079529518 @default.
• W2588893060 creator A5085665866 @default.
• W2588893060 creator A5090367243 @default.
• W2588893060 date "2010-11-19" @default.
• W2588893060 modified "2023-10-01" @default.
• W2588893060 title "Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic Significance" @default.
• W2588893060 doi "https://doi.org/10.1182/blood.v116.21.172.172" @default.
• W2588893060 hasPublicationYear "2010" @default.
• W2588893060 type Work @default.
• W2588893060 sameAs 2588893060 @default.
• W2588893060 citedByCount "18" @default.
• W2588893060 countsByYear W25888930602012 @default.
• W2588893060 countsByYear W25888930602013 @default.
• W2588893060 countsByYear W25888930602014 @default.
• W2588893060 countsByYear W25888930602015 @default.
• W2588893060 countsByYear W25888930602016 @default.
• W2588893060 crossrefType "journal-article" @default.
• W2588893060 hasAuthorship W2588893060A5000000264 @default.
• W2588893060 hasAuthorship W2588893060A5000436961 @default.
• W2588893060 hasAuthorship W2588893060A5003760824 @default.
• W2588893060 hasAuthorship W2588893060A5004450449 @default.
• W2588893060 hasAuthorship W2588893060A5007895303 @default.
• W2588893060 hasAuthorship W2588893060A5010990164 @default.
• W2588893060 hasAuthorship W2588893060A5015832963 @default.
• W2588893060 hasAuthorship W2588893060A5025168447 @default.
• W2588893060 hasAuthorship W2588893060A5025907897 @default.
• W2588893060 hasAuthorship W2588893060A5027248801 @default.
• W2588893060 hasAuthorship W2588893060A5030574503 @default.
• W2588893060 hasAuthorship W2588893060A5035348501 @default.
• W2588893060 hasAuthorship W2588893060A5037324033 @default.
• W2588893060 hasAuthorship W2588893060A5037888163 @default.
• W2588893060 hasAuthorship W2588893060A5039996784 @default.
• W2588893060 hasAuthorship W2588893060A5042552205 @default.
• W2588893060 hasAuthorship W2588893060A5045283637 @default.
• W2588893060 hasAuthorship W2588893060A5052564121 @default.
• W2588893060 hasAuthorship W2588893060A5055343627 @default.
• W2588893060 hasAuthorship W2588893060A5064625563 @default.
• W2588893060 hasAuthorship W2588893060A5066213019 @default.
• W2588893060 hasAuthorship W2588893060A5067318724 @default.
• W2588893060 hasAuthorship W2588893060A5076521693 @default.
• W2588893060 hasAuthorship W2588893060A5076870917 @default.
• W2588893060 hasAuthorship W2588893060A5078817313 @default.
• W2588893060 hasAuthorship W2588893060A5079529518 @default.
• W2588893060 hasAuthorship W2588893060A5085665866 @default.
• W2588893060 hasAuthorship W2588893060A5090367243 @default.
• W2588893060 hasConcept C126322002 @default.
• W2588893060 hasConcept C2776694085 @default.
• W2588893060 hasConcept C2776755627 @default.
• W2588893060 hasConcept C2777583451 @default.
• W2588893060 hasConcept C2778729363 @default.
• W2588893060 hasConcept C2779429289 @default.
• W2588893060 hasConcept C2779536868 @default.
• W2588893060 hasConcept C2780401358 @default.
• W2588893060 hasConcept C71924100 @default.
• W2588893060 hasConcept C90924648 @default.
• W2588893060 hasConcept C98274493 @default.
• W2588893060 hasConceptScore W2588893060C126322002 @default.
• W2588893060 hasConceptScore W2588893060C2776694085 @default.
• W2588893060 hasConceptScore W2588893060C2776755627 @default.
• W2588893060 hasConceptScore W2588893060C2777583451 @default.
• W2588893060 hasConceptScore W2588893060C2778729363 @default.
• W2588893060 hasConceptScore W2588893060C2779429289 @default.
• W2588893060 hasConceptScore W2588893060C2779536868 @default.
• W2588893060 hasConceptScore W2588893060C2780401358 @default.
• W2588893060 hasConceptScore W2588893060C71924100 @default.
• W2588893060 hasConceptScore W2588893060C90924648 @default.
• W2588893060 hasConceptScore W2588893060C98274493 @default.
• W2588893060 hasLocation W25888930601 @default.
• W2588893060 hasOpenAccess W2588893060 @default.
• W2588893060 hasPrimaryLocation W25888930601 @default.
• W2588893060 hasRelatedWork W1993808217 @default.
• W2588893060 hasRelatedWork W1994309500 @default.
• W2588893060 hasRelatedWork W2000116184 @default.

• next